Biotechnology Stock News
Categories
- All
- Editor's Picks
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus News Biotechnology
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial Resilience
Acelyrin Inc (SLRN) prioritizes its lead product candidate for thyroid eye disease while maintaining a strong cash position to support future developments. Nov 14, 2024
GuruFocus News Biotechnology
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and Financial Resilience Amid Challenges
Despite a net loss, Taysha Gene Therapies Inc (TSHA) shows promising advancements in Rett syndrome treatment and maintains a strong cash position. Nov 14, 2024
GuruFocus News Biotechnology
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring and Promising Trial Results
Adaptimmune Therapeutics PLC (ADAP) outlines a path to operating breakeven by 2027, driven by strategic restructuring and promising outcomes from the IGNYTE-ESO trial. Nov 14, 2024
GuruFocus News Biotechnology
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amidst Financial Challenges
scPharmaceuticals Inc (SCPH) reports a 24% revenue increase and strategic advancements, despite facing significant net losses and operational hurdles. Nov 14, 2024
GuruFocus News Biotechnology
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and Financial Growth
Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. Nov 14, 2024
GuruFocus News Biotechnology
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical Progress Amid Financial Challenges
Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased net losses and operational uncertainties. Nov 14, 2024
GuruFocus News Biotechnology
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Operational Challenges
Jaguar Health Inc (JAGX) reports increased revenue and strategic product launches, while navigating financial losses and regulatory hurdles. Nov 14, 2024
GuruFocus News Biotechnology
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Financial Challenges
Despite a strong cash position and promising pipeline developments, Fulcrum Therapeutics Inc (FULC) faces hurdles with reduced revenues and ongoing net losses. Nov 14, 2024